SAM
NTLA icon

Smartleaf Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Smartleaf Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Hold
627
– – ﹤0.01% 2343
2026
Q1 		$7.3K Buy
627
+424
+209% +$5.4K ﹤0.01% 2468
2025
Q4 		$1.84K Buy
203
+104
+105% +$1.43K ﹤0.01% 3009
2025
Q3 		$1.68K Buy
99
+72
+267% +$887 ﹤0.01% 2652
2025
Q2 		$258 Sell
27
-23
-46% -$189 ﹤0.01% 2644
2025
Q1 		$403 Hold
50
– – ﹤0.01% 2729
2024
Q4 		$570 Sell
50
-366
-88% -$5.71K ﹤0.01% 2765
2024
Q3 		$8.74K Buy
416
+252
+154% +$5.81K ﹤0.01% 1838
2024
Q2 		$3.8K Buy
+164
New +$3.9K ﹤0.01% 1935

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Smartleaf Asset Management's NTLA Position: Q2 2026 in Review

Smartleaf Asset Management held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 627 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2343.

Smartleaf Asset Management first reported a position in NTLA in Q2 2024 and has held it in 9 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Smartleaf Asset Management held 627 shares of Intellia Therapeutics worth $10.4K as of Q2 2026.
  • Smartleaf Asset Management left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2343 holding.
  • Smartleaf Asset Management first reported a position in Intellia Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.